Clinical Trial Goal
To find out:
- The highest dose of ASTX727 that's safe to give with nivolumab
- If the combination of ASTX727 and nivolumab is safe and works well to treat lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years and older
- Have one of the following that has relapsed or is refractory:
- B-cell lymphoma. Some examples are:
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Mantle cell lymphoma (MCL)
- Small lymphocytic lymphoma (SLL)
- Hodgkin lymphoma
- B-cell lymphoma. Some examples are:
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ASTX727 is the combination of cedazuridine and decitabine.
Cedazuridine is a drug that blocks CDA in certain cells.
Decitabine is is a drug that blocks the growth of cancer cells.
Nivolumab is a checkpoint inhibitor that targets PD-1 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Cedazuridine is a drug that blocks CDA in certain cells.
Decitabine is is a drug that blocks the growth of cancer cells.
Nivolumab is a checkpoint inhibitor that targets PD-1 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- ASTX727– A pill that you take by mouth one time each day for 3-5 days
- Nivolumab– Given as an intravenous (IV) infusion 1 time
You may continue treatment for up to 2 years. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using ASTX727 and nivolumab together to treat lymphoma that has relapsed or is refractory is new and unproven.
Locations
Sponsors
lead: National Cancer Institute (NCI)
